Physician profile
Hasan Raza
NPI 1710382601
$1,479.84
in general payments reported to CMS, 2019-2025
12 companies · $386 in 2025
The $386 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $117 · 2022: $204 · 2023: $428 · 2024: $345 · 2025: $386.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,159.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,158.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $277.94 | 2021-2025 | |
| Lundbeck LLC | $220.55 | 2023-2025 | Rexulti, Brintellix |
| Axsome Therapeutics, INC. | $202.30 | 2022-2025 | Auvelity |
| Alkermes, INC. | $184.41 | 2023-2025 | Aristada, Lybalvi, Aristada Initio |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $170.80 | 2022-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $123.31 | 2024-2025 | Ingrezza |
| E.R. Squibb & Sons, L.L.C. | $105.01 | 2024-2025 | Cobenfy |
| Supernus Pharmaceuticals, INC. | $55.33 | 2023-2024 | Qelbree, Qelbree |
| Teva Pharmaceuticals USA, INC. | $49.02 | 2021 | |
| Harmony Biosciences LLC | $41.73 | 2022 | |
| Corium, LLC | $27.65 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $21.79 | 2024 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hasan Raza listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.